Insulin prices in India could go up atleast by 15%.
National Pharmaceutical Pricing Authority (NPPA) has allowed insulin producers to hike the maximum retail prices (MRP) of several popular insulin brands by up to 15%, reports said.
Leading insulin producers such as Novo Nordisk, Torrent Pharma, MJ Biopharm, Shreya Life Sciences and Sanofi Aventis Pharma.
Torrent Pharma’s brand Human Mixtard (30/70) has been increased by 10% to Rs 169 from Rs 153 per vial.
Novo Nordisk will hike the price of three brands — Actrapid Flex Pen, Insulatard Flex Pen and Mixtard 30 Flex Pen — by up to 15% to Rs 1,639 (containing 5 injections).
The revised prices will come into effect within within 15 days of the notification.
India, which has about 50 million diabetes patients, is expected to have nearly 9% of the country’s population affected by the disease by 2030, says a recent study by the International Diabetes Federation (IDF).
Apart from diabetes drugs, Wockhardt’s anti-spasm brand Spasmo Proxyvon and Proxyvon capsules, Cipla’s Theophylline syrup, Novartis’ Vitalux Plus TR and Pfizer’s Medrol brands.
The ceiling price of various strengths and packs of chlorpromazine with combinations, sulfsalazine, ascorbic acid with combinations, prednisolone, naproxen sodium, dextropropoxyphene HCl capsule and tablet forms with combinations, levosalbutamol with combinations, erythromycin estolate, gentamycin with combinations, dexamethasone sodium and Ofloxacin with combinations has also been revised through notification.
Further, through another notification, NPPA has revised prices for a range of bulk drugs including vitamin A palmitate and vitamin A acetate with quantity 1000 MIU and norfloxacin, pentoxyphylline, Vitamin C and sodium ascorbate, famotidine and phenyl butazone per kilo gram.
The ceiling and non ceiling prices for the formulation packs were fixed through two notifications, one in the beginning of December 2009 and the latest on January 21, 2010. The prices for bulk drugs were notified on January 20, 2010.
Official Gazette and all formulators utilizing these drugs in their scheduled formulations are advised to follow the provisions of DPCO, 1995, orders the NPPA notification.